Aurobindo Pharma to host investor meet at Elara India Dialogue 2026

0 min read | Published on 25 Aug 2026, 05:05 PM |Updated on 25 Aug 2026, 06:57 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

Aurobindo Pharma will host investors at the Ashwamedh – Elara India Dialogue 2026
The event is scheduled for September 1, 2026, in Mumbai
Meetings will run from 9:00 am to 5:00 pm
No unpublished price sensitive information will be discussed

*this image is generated using AI for illustrative purposes only.

Aurobindo Pharma will participate in the Ashwamedh – Elara India Dialogue 2026 on September 1, 2026. The company’s officials are scheduled to hold one-on-one and group meetings with investors in Mumbai.

The interaction is set to run from 9:00 am to 5:00 pm. The firm confirmed that no unpublished price sensitive information (UPSI) will be discussed during these sessions.

Event Details

The meeting forms part of the broader Ashwamedh – Elara India Dialogue 2026 agenda. Company representatives will engage directly with analysts and institutional investors.

Date	Time	Meeting Name	Type	Location
September 1, 2026	9:00 am to 5:00 pm	Ashwamedh – Elara India Dialogue 2026	One-on-one and Group meetings	Mumbai

Schedule Changes

The company noted that the schedule remains subject to change. Any modifications may occur due to exigencies on the part of either the investor or the company.

Historical Stock Returns for Aurobindo Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.19%	+2.00%	+4.16%	+35.02%	+51.78%	0.0%

Disclaimer: This article is AI-generated using data from LiveSquawk. ScanX is not liable for any inaccuracies.

How might the strategic priorities discussed by Aurobindo Pharma's leadership at the Ashwamedh – Elara India Dialogue influence their near-term R&D investment plans?

What specific growth drivers in emerging markets or generic drug segments are analysts likely to probe during these one-on-one investor meetings?

Could insights shared regarding global regulatory compliance or supply chain resilience impact Aurobindo Pharma's valuation multiples in the weeks following the event?

Aurobindo Pharma

View Company Insights

View All News

Aurobindo Pharma subsidiary Lannett faces four US FDA compliance issues

0 min read | Published on 24 Aug 2026, 09:26 AM |Updated on 24 Aug 2026, 09:26 AM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Aurobindo Pharma's subsidiary Lannett Company LLC received four compliance observations from the US FDA
The findings emerged following a US FDA inspection of the Lannett facility
The development signals regulatory scrutiny at the subsidiary level

*this image is generated using AI for illustrative purposes only.

Aurobindo Pharma 's subsidiary, Lannett Company LLC, has received four compliance observations following a US FDA inspection.

Regulatory findings at Lannett Company LLC

The US Food and Drug Administration conducted an inspection of Lannett Company LLC, a subsidiary of Aurobindo Pharma, and identified four compliance issues at the facility. The development reflects regulatory scrutiny directed at the subsidiary's operations.

Parameter	Details
Entity inspected	Lannett Company LLC
Parent company	Aurobindo Pharma
Regulatory authority	US FDA
Number of compliance issues	Four

Context of the inspection

Lannett Company LLC operates as a subsidiary of Aurobindo Pharma and is subject to periodic inspections by the US FDA as part of standard regulatory oversight of pharmaceutical manufacturing and related operations. The four compliance observations noted during this inspection represent areas requiring the company's attention and response to the regulator.

Historical Stock Returns for Aurobindo Pharma